Skip to NavigationSkip to content

Boehringer withdraws its £700m investment in Hikma Pharmaceuticals

Published on 23/06/20 at 12:07pm

Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the company poised to sell 28 million shares to the value of around £70 million to institutional investors.  

The decision represents the rolling back of a partnership that was struck back in 2016. Hikma responded to Boehringer’s move by announcing that it would be initiating a ‘buy back’ of up to £295 million of its shares, funding the transaction through cash and other available facilities. The shares will be acquired equal to the value they are sold to other investors.

Hikma said it had also entered into a separate deal with Boehringer to receive a 2% commitment fee of the total value of the buy back shares.

The shares were originally acquired by Boehringer in 2016 as part of the consideration for its acquisition of Roxane Laboratories, as Said Darwazah, Executive Chairman of Hikma, noted in his statement following the company’s recent decision.

“I would like to thank Boehringer Ingelheim for their support as a major shareholder in Hikma since our acquisition of Roxane in 2016. We are delighted to have the opportunity to welcome new investors into Hikma and at the same time have this unique opportunity to acquire a significant proportion of our share capital,” he said. “The buy back reflects our confidence in the future prospects of the business and we will retain significant financial flexibility to continue to execute our strategy. We remain focused on delivering future growth and value creation for our shareholders.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches